2023
Breast Carcinoma With Tubulopapillary Features Has a Distinct Immunophenotypic and Molecular Signature: A Report of Two Tumors and Literature Review
Carrasco-Tenezaca F, Moreira-Dinzey J, Manrai P, Bearse M, Burela S, Podany P, Singh K, Pareja F, Zheng J, Muscato N, Liang Y, Zhan H, Krishnamurti U, Dolezal D, Wang J, Harigopal M. Breast Carcinoma With Tubulopapillary Features Has a Distinct Immunophenotypic and Molecular Signature: A Report of Two Tumors and Literature Review. International Journal Of Surgical Pathology 2023, 32: 1037-1045. PMID: 37908113, DOI: 10.1177/10668969231209780.Peer-Reviewed Original ResearchBreast carcinomaTubulopapillary featuresHuman epidermal growth factor 2 (HER2) expressionBreast cancer histologic subtypesNonmetastatic breast carcinomaTriple-negative profileHigh-grade nuclear featuresTriple-negative carcinomasHigh-grade featuresMetastatic breast carcinomaGrowth factor 2 expressionFactor 2 expressionReports of tumorsMicropapillary projectionsNeoadjuvant therapyHistologic subtypeWorse prognosisFirst tumorPoor prognosisAdditional tumorsInvasive carcinomaEstrogen receptorCarcinomaPathogenic variantsTumorsThe correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas
Moreira-Dinzey J, Zhan H, Rozenblit M, Krishnamurti U, Harigopal M, Zhong M, Liang Y. The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas. Human Pathology 2023, 137: 56-62. PMID: 37127079, DOI: 10.1016/j.humpath.2023.04.017.Peer-Reviewed Original ResearchConceptsMetastatic tumorsBreast carcinomaGenetic aberrationsPR statusPrimary tumorBreast cancerControl groupER/PR statusEstrogen receptor-positive breast carcinomasER-positive breast cancerER positivity rateMetastatic breast cancerProgesterone receptor statusMetastatic breast carcinomaMore liver metastasesPrimary breast carcinomaWild-type groupEstrogen receptor 1 geneReceptor 1 geneWild-type controlsLiver metastasesReceptor statusClinicopathological featuresER expressionControl tumors
2017
GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma
Bivin W, Yergiyev O, Bunker M, Silverman J, Krishnamurti U. GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma. Applied Immunohistochemistry & Molecular Morphology 2017, 25: 553-558. PMID: 26945445, DOI: 10.1097/pai.0000000000000349.Peer-Reviewed Original ResearchConceptsInvasive breast carcinomaHER2 amplificationHER2 overexpressionER negativityPathologic stageHistologic gradeP53 positivityGRB7 expressionBreast cancerBreast carcinomaInvasive breast cancer correlatesInvasive breast cancerBreast cancer correlatesChromosome 17 copy numberAntiestrogen therapyPR expressionPredictive factorsHER2 expressionCancer correlatesPR testingP53 immunohistochemistryAggressive phenotypeHER2 geneHER2P53 statusHormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients
Li X, Yang J, Krishnamurti U, Huo L, Ward K, O'Regan R, Peng L. Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients. Clinical Breast Cancer 2017, 17: 356-366. PMID: 28576631, DOI: 10.1016/j.clbc.2017.03.005.Peer-Reviewed Original ResearchConceptsMale breast carcinomaFemale breast carcinomaHormone receptorsMBC patientsWorse OSOverall survivalBreast carcinomaBreast cancerStage IHormone receptor-positive breast cancerEarly-stage hormone receptorReceptor-positive breast cancerNational Cancer Institute's SurveillanceEnd Results (SEER) databaseWorse overall survivalBreast carcinoma casesSimilar survival ratesMBC subtypesWorse survivalClinicopathologic featuresOverall incidenceResults databaseWorse prognosisHER2 statusFBC patients
2015
GATA3 Immunohistochemistry Expression in Histologic Subtypes of Primary Breast Carcinoma and Metastatic Breast Carcinoma Cytology
Deftereos G, Ramirez A, Silverman J, Krishnamurti U. GATA3 Immunohistochemistry Expression in Histologic Subtypes of Primary Breast Carcinoma and Metastatic Breast Carcinoma Cytology. The American Journal Of Surgical Pathology 2015, 39: 1282-1289. PMID: 26274030, DOI: 10.1097/pas.0000000000000505.Peer-Reviewed Original ResearchConceptsTriple-negative breast carcinomaGCDFP-15Breast carcinomaCytology casesGynecologic malignanciesER expressionHistologic subtypeExpression correlatesMetastatic gynecologic malignanciesMetastatic breast carcinomaNegative breast carcinomaPrimary breast carcinomaStaining scoresNegative carcinomasOvarian carcinomaImmunohistochemistry expressionHistology casesMammaglobinCarcinomaIntensity scoresGATA3 expressionSubtypesGATA3Cancer cellsBreast
2014
The Clinicopathologic Significance of Centromere 17 Copy Number Alterations in Invasive Breast Carcinoma
Krishnamurti U, Silverman J. The Clinicopathologic Significance of Centromere 17 Copy Number Alterations in Invasive Breast Carcinoma. Advances In Anatomic Pathology 2014, 19: 13-17. DOI: 10.1097/pcr.0000000000000016.Peer-Reviewed Original ResearchAdverse prognostic factorHER2 amplificationBreast cancerPrognostic factorsHuman epidermal growth factor receptor 2 (HER2) oncoproteinCopy number alterationsInvasive breast cancerInvasive breast carcinomaHER2/CEP17HER2 gene amplificationNumber alterationsHER2 copy numberChromosome 17 polysomyCEP17 duplicationMost patientsHER2 overexpressionBreast carcinomaClinicopathologic significanceHER2 2Chromosome 17PatientsCancerProtein overexpressionCopy numberHER2
2011
Correlation of Immunohistochemical Expression of p53 With Unamplified Chromosome 17 Polysomy in Invasive Breast Carcinoma
Krishnamurti U, Zarineh A, Atem F, Silverman J. Correlation of Immunohistochemical Expression of p53 With Unamplified Chromosome 17 Polysomy in Invasive Breast Carcinoma. Applied Immunohistochemistry & Molecular Morphology 2011, 19: 28-32. PMID: 20823770, DOI: 10.1097/pai.0b013e3181e9bb6f.Peer-Reviewed Original ResearchConceptsInvasive breast carcinomaChromosome 17 polysomyBreast carcinomaHER2 amplificationReceptor negativityPrognostic indicatorNottingham scoreBreast cancerNeck squamous cell carcinomaNonsmall cell lung carcinomaHormone receptor negativityAdverse prognostic indicatorEstrogen receptor negativitySquamous cell carcinomaIndependent prognostic indicatorCell lung carcinomaCell carcinomaP53 positivityBladder carcinomaP53 immunostainingP53 overexpressionImmunohistochemical expressionLung carcinomaCarcinomaP53 expression
2009
Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma
Krishnamurti U, Hammers J, Atem F, Storto P, Silverman J. Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Modern Pathology 2009, 22: 1044-1048. PMID: 19396150, DOI: 10.1038/modpathol.2009.61.Peer-Reviewed Original ResearchConceptsInvasive breast carcinomaChromosome 17 polysomyBreast carcinomaHER2 gene amplificationBreast cancerChromosome 17 aneusomyHuman epidermal growth factor receptor 2 (HER2) oncoproteinAdverse prognostic factorAdverse prognostic indicatorEstrogen receptor negativityTreatment of patientsHigh nuclear gradePoor prognostic significanceGene amplificationPaucity of literatureReceptor negativityMost patientsPathologic factorsPrognostic factorsPredictive factorsPrognostic significanceHistologic gradePrognostic indicatorTumor stageHER2 overexpression